- Home
- ENVX vs HRMY Comparison
ENVX vs HRMY Comparison
Compare ENVX & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENVX
- HRMY
- Stock Information
- Founded
- ENVX 2006
- HRMY 2017
- Country
- ENVX United States
- HRMY United States
- Employees
- ENVX N/A
- HRMY N/A
- Industry
- ENVX Industrial Machinery/Components
- HRMY Biotechnology: Pharmaceutical Preparations
- Sector
- ENVX Miscellaneous
- HRMY Health Care
- Exchange
- ENVX Nasdaq
- HRMY Nasdaq
- Market Cap
- ENVX 1.6B
- HRMY 2.0B
- IPO Year
- ENVX N/A
- HRMY 2020
- Fundamental
- Price
- ENVX $11.43
- HRMY $34.97
- Analyst Decision
- ENVX Strong Buy
- HRMY Buy
- Analyst Count
- ENVX 10
- HRMY 9
- Target Price
- ENVX $21.60
- HRMY $44.11
- AVG Volume (30 Days)
- ENVX 5.7M
- HRMY 630.7K
- Earning Date
- ENVX 11-05-2024
- HRMY 10-29-2024
- Dividend Yield
- ENVX N/A
- HRMY N/A
- EPS Growth
- ENVX N/A
- HRMY N/A
- EPS
- ENVX N/A
- HRMY 1.95
- Revenue
- ENVX $16,620,999.00
- HRMY $656,109,000.00
- Revenue This Year
- ENVX $175.94
- HRMY $24.37
- Revenue Next Year
- ENVX $158.55
- HRMY $18.76
- P/E Ratio
- ENVX N/A
- HRMY $17.85
- Revenue Growth
- ENVX 1327.92
- HRMY 31.52
- 52 Week Low
- ENVX $5.70
- HRMY $18.79
- 52 Week High
- ENVX $18.68
- HRMY $40.60
- Technical
- Relative Strength Index (RSI)
- ENVX 54.33
- HRMY 44.00
- Support Level
- ENVX $10.51
- HRMY $33.56
- Resistance Level
- ENVX $13.19
- HRMY $36.16
- Average True Range (ATR)
- ENVX 1.03
- HRMY 1.47
- MACD
- ENVX 0.09
- HRMY -0.19
- Stochastic Oscillator
- ENVX 62.47
- HRMY 22.02
About ENVX Enovix Corporation
Enovix Corp is engaged in the business of advanced silicon-anode lithium-ion battery development and production. It is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable the widespread utilization of renewable energy.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.